Cases & Deals

  • Home
  • Practices
  • AbbVie partners to develop in-situ CAR-T cell therapies

Share

AbbVie partners to develop in-situ CAR-T cell therapies

January 2024

Client(s) AbbVie Inc.

Jones Day advised AbbVie Inc. on IP due diligence in connection with its strategic collaboration and option agreements with Umoja Biopharma, a transaction valued at up to $1.44 billion. The transaction involved AbbVie obtaining rights to Umoja's proprietary gene delivery platform for in-situ CAR-T cell therapies, including exclusive options to license clinical-stage and discovery-phase candidates.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.